Clinical Research Directory

Inclusion Criteria: Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system. Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations. No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered. ECOG PS scores of the enrolled patients ranged from 0 to 2. Exclusion Criteria: Patients with other previous malignancies did not require additional treatment. Patients with incomplete key baseline and treatment information:including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant. Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.